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This dose escalation study was designed to determine the recommended dose of the multi-targeted cell cycle inhibitor indisulam in
combination with capecitabine in patients with solid tumours and to evaluate the pharmacokinetics of the combination. Thirty-five
patients were treated with indisulam on day 1 of each 21-day cycle. Capecitabine was administered two times daily (BID) on days
1–14. Plasma concentrations of indisulam, capecitabine and its three metabolites were determined for pharmacokinetic analysis. The
main dose-limiting toxicity was myelosuppression. Hand/foot syndrome and stomatitis were the major non-haematological toxicities.
The recommended dose was initially established at indisulam 700mgm
 2 and capecitabine 1250mgm
 2 BID. However, during cycle
2 the recommended dose was poorly tolerated in three patients. A dose of indisulam 500mgm
 2 and capecitabine 1250mgm
 2
BID proved to be safe at cycle 1 and 2 in nine additional patients. Indisulam pharmacokinetics during cycle 1 were consistent with
pharmacokinetic data from phase I mono-therapy studies. However, exposure to indisulam was remarkably increased at cycle 2 due
to a drug–drug interaction between capecitabine and indisulam. Partial response was confirmed in two patients, one with colon
carcinoma and the other with pancreatic carcinoma. Seventeen patients had stable disease. Indisulam (700mgm
 2) in combination
with capecitabine (1250mgm
 2 BID) was well tolerated during the first cycle. A dose of indisulam 500mgm
 2 and capecitabine
1250mgm
 2 BID was considered safe in multiple treatment cycles. The higher incidence of toxicities observed during cycle 2 can be
explained by a time-dependent pharmacokinetic drug–drug interaction.
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Deregulation of the cell cycle commonly occurs during tumour
development, resulting in unrestricted cell proliferation (Sherr,
1996; Lundberg and Weinberg, 1999; Owa et al, 2001). Cyclin-
dependent kinases (CDKs) in concert with cyclin proteins control
the progression of the cell cycle. CDK inhibitors have the potential
to induce cell cycle arrest and apoptosis in tumour cells. Indisulam
is a chloro-indoyl sulphonamide anticancer agent that inhibits the
phosphorylation of CDK2 and decreases the expression of cyclin E
(Ozawa et al, 2001). This is accompanied by hypophosphorylation
of the retinoblastoma protein. Indisulam also reduces the
expression of cyclins A, B1 and H. This ultimately results in cell
cycle arrest at multiple checkpoints. At higher concentrations,
treatment with indisulam was associated with upregulation of p53
and p21 resulting in apoptotic cell death (Fukuoka et al, 2001;
Ozawa et al, 2001).
Potent tumour growth inhibition has been demonstrated in both
in vitro and in vivo models (Ozawa et al, 2001).
Indisulam was clinically evaluated in five phase I studies in
patients with refractory solid tumours and in several phase II
studies including patients with colorectal cancer, breast cancer,
head and neck cancer, NSCLC, renal cell cancer and metastatic
melanoma (Raymond et al, 2000, 2002; Punt et al, 2001;
Mainwaring et al, 2002; Dittrich et al, 2003; Fumoleau et al,
2003; Terret et al, 2003; Haddad et al, 2004; Raftopoulos et al, 2004;
Smyth et al, 2005; Yamada et al, 2005; Talbot et al, 2007).
Reversible neutropenia and thrombocytopenia were the dose-
limiting toxicities in all schedules. The maximum-tolerated dose
(MTD) of indisulam was established at 800mgm
 2 when given as a
one-hour infusion once every 3 weeks (Raymond et al, 2002). A
dose of 700mgm
 2 was considered safe for further studies and was
evaluated in the phase II programme (Mainwaring et al, 2002;
Fumoleau et al, 2003; Haddad et al, 2004; Raftopoulos et al, 2004;
Smyth et al, 2005; Talbot et al, 2007). Although indisulam was well
tolerated, it had only minor to moderate single agent activity in
several phase II studies (Mainwaring et al, 2002; Fumoleau et al,
2003; Haddad et al, 2004; Raftopoulos et al, 2004; Smyth et al,
2005; Talbot et al, 2007).
Currently, the combination of indisulam with several classes of
antineoplastic drugs is being investigated. The combination of
indisulam with capecitabine showed additive effects in preclinical
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sstudies when both agents were given simultaneously or when
indisulam was given prior to capecitabine, which might be
explained by downregulation of thymidylate synthetase by
indisulam (Ozawa et al, 2004). On the basis of the preclinical
data, the different mechanisms of antitumor activity of indisulam
and capecitabine and the largely non-overlapping toxicity profiles,
the current phase I trial was performed with this combination. The
primary objectives were: (i) to determine the recommended dose
and (ii) to evaluate the pharmacokinetic profiles of indisulam and
capecitabine. An additional objective was to explore preliminary
activity of this combination.
PATIENTS AND METHODS
Eligibility
Patients were eligible if they had a histologically or cytologically
confirmed solid tumour refractory to standard therapy or for
whom no established therapy existed. Previous anticancer
radiotherapy or chemotherapy had to be discontinued for at least
4 weeks before entry into the study. Prior capecitabine therapy was
allowed, but a severe or unexpected reaction to fluoropyrimidine
therapy was an exclusion criterion. Maximal two prior lines of
myelosuppressive chemotherapy were allowed. Patients had to
have acceptable bone marrow, renal and hepatic functions. The
study protocol was approved by the medical ethics committees
of the participating hospitals and all patients gave written
informed consent (World Medical Association Declaration of
Helsinki, 2002).
Treatment plan and study design
The recommended dose of indisulam in combination with
capecitabine was determined by dose escalation. Patients were
initially treated in cohorts of three per dose level. Each cycle
consisted of 3 weeks of therapy. The starting doses were
350mgm
 2 of indisulam given as a 1-h infusion on day 1 and
1000mgm
 2 BID of capecitabine given on days 1–14, repeated 3
weekly. On day 1, the start of the infusion of indisulam and the oral
administration of capecitabine were simultaneous. In the next
cohort, the dose of capecitabine was escalated to 1250mgm
 2 BID,
which is the recommended dose for treatment of colon, colorectal
and breast cancer. In subsequent cohorts, the dose of indisulam
was escalated to 500, 600, 700 and 800mgm
 2 when permitted by
the toxicity profile of the combination. If one of the first three
patients experienced dose-limiting toxicity (DLT) during cycle 1,
the cohort was expanded to six patients. Provided that none of the
additional three patients experienced a DLT during cycle 1, dose
escalation was continued. Patients who did not experience
significant toxicities at their initial dose were permitted to receive
a dose escalation. The MTD was defined as the dose level at which
two or more patients in the expanded cohort of six patients
experienced a DLT. The dose level below the MTD was
recommended for phase II evaluation.
Patient evaluation and follow-up
Complete patient history, physical examination, performance
status, haematological analysis, blood chemistry and urinalysis
were performed at baseline. Electrocardiogram (ECG) recordings
were taken pre-dose and within 1h after the end of the indisulam
infusion in cycle 1. Computed tomography, magnetic resonance
imaging scans or photography for skin lesions were performed to
clearly document the location, size and extent of the disease.
Laboratory tests were performed on day 1, 8 and 15 of each
treatment cycle. Tumour assessments were performed every other
cycle and were evaluated according to the RECIST criteria
(Therasse et al, 2000). Adverse events were evaluated throughout
the study and were graded according to the National Cancer
Institute Common Toxicity Criteria version 2.0 (Cancer Therapy
Evaluation Program, 1998).
DLT was defined as: grade 3 or 4 non-haematological toxicity
(excluding alopecia and untreated nausea and vomiting), grade 4
thrombocytopenia, grade 4 neutropenia lasting 7 days or more and
grade 3 or 4 febrile neutropenia. These events were indicated as
DLT only if observed during the first cycle of treatment or during
cycle 2 for patients who underwent intra-patient dose escalation.
Pharmacokinetic study
Full pharmacokinetic sampling of indisulam and capecitabine were
performed during the first cycle of treatment. For patients who
underwent a dose escalation at cycle 2, full pharmacokinetic
sampling was repeated in the first cycle at the increased dose.
Blood samples for indisulam analysis were obtained at 16 time
points for up to 8 days after the first administration: pre-infusion,
30min after the start of infusion, at the end of the infusion, at 10
and 30min and at 1, 2, 4, 6, 8, 24, 48, 72, 96, 120 and 168h after the
end of the infusion. The concentrations of indisulam in plasma
were measured using high-performance liquid chromatography
coupled to an electrospray ionisation tandem mass spectrometer
(LC/ESI-MS/MS) as described previously (Beumer et al, 2004).
Blood samples for capecitabine analysis were obtained at 10 time
points on day 1: before administration, at 15 and 30min and at 1,
2, 3, 4, 5, 7 and 9h after administration. Plasma concentrations
of capecitabine and its metabolites 50-deoxy-5-fluorocytidine
(50-DFCR), 50-deoxy-5-fluorouridine (50-DFUR) and 5-fluorouracil
(5-FU) were determined by high-performance liquid chromato-
graphy with UV detection (Reigner et al, 1998).
Population pharmacokinetic analysis
The population pharmacokinetic analyses were performed using
NONMEM software (version V, level 1.1) (GloboMax LLC,
Hannover, USA) (Beal et al, 1988). A population pharmacokinetic
model was developed previously to describe the pharmacokinetic
profile of indisulam mono-therapy (Zandvliet et al, 2006). The
pharmacokinetic parameters describing the model for indisulam
mono-therapy were applied to calculate model predicted indisulam
concentrations, which were compared to the observed plasma
concentration of indisulam. If the model adequately predicted the
observed concentrations, it could be concluded that the pharmaco-
kinetic profile of indisulam was not highly influenced by
combination therapy with capecitabine.
The pharmacokinetic results of capecitabine and its metabolites
were also evaluated by compartmental analysis using NONMEM
software to adequately describe the absorption phase. A time delay
was observed between drug intake and the appearance of
capecitabine in plasma. Therefore, a first-order absorption model
with lag-time was applied to all data. Individual areas under the
concentration vs time curve (AUCs) and terminal half-lives were
assessed by fitting a one- or two-compartment model to the
concentration time profiles in individual patients. The current data
were compared to previously published results to evaluate any
potential pharmacokinetic interaction with indisulam.
Pharmacokinetic–pharmacodynamic analysis
The correlation between drug exposure and CTC grade 3 and 4
adverse events was explored to find potential relationships
between pharmacokinetics and safety parameters. The AUC was
used as a measure of exposure to indisulam in this analysis. For
capecitabine, the AUC of 50-DFUR was previously found to be
predictive of toxicities and was therefore used in the current
analysis to assess relationships between exposure to capecitabine
and adverse events (Gieschke et al, 1998).
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sRESULTS
Dose escalation and safety assessment
In total, 35 patients were included in the study. Patient
characteristics are shown in Table 1. All patients were evaluable
for toxicity. Patients were initially treated at six different dose-
levels (level 1–6) (Table 2a). The number of treatment cycles per
patient (median¼3, range 1–15) is summarised in Table 2b. In
total, patients received 159 cycles.
Dose levels 1, 2 and 3 were well tolerated. A patient who had an
intra-patient dose escalation from level 3 to level 4 experienced
dose limiting toxicity at the escalated dose: febrile neutropenia
grade 3 and thrombocytopenia grade 3. Another patient with
thymoma died due to cardiac arrhythmia during indisulam
infusion at cycle 1. It could not be precluded that this serious
adverse event was related to study medication. For safety reasons,
patients at level 4 were further treated at level 3. Two additional
patients were treated at dose level 3. Normal dose escalation was
resumed and continued up to dose level 6 (800mgm
 2 indisulam).
The first two patients treated at dose level 6 both experienced
serious haematological toxicity. One patient had febrile neutro-
penia grade 3, neutropenia grade 4, leukocytopenia grade 3 and
thrombocytopenia grade 3 and the other patient had febrile
neutropenia grade 4, leukocytopenia grade 4, thrombocytopenia
grade 3 and neutropenia grade 4. Because of safety reasons, it was
decided not to further expand dose level 6 and this dose level was
established as the MTD.
At the immediate lower dose level of 700mgm
 2 indisulam in
combination with 1250mgm
 2 BID capecitabine, four patients
were additionally treated. This level was well tolerated at cycle 1.
Conversely, all four patients experienced severe toxicities during
cycle 2. Three patients had severe haematological and non-
haematological toxicities at cycle 2 and consequently dose
reduction of both drugs; all three patients had neutropenia grade
4, thrombocytopenia grade 3 or 4, leukocytopenia grade 3 or 4 and
hand/foot reaction grade 3 or 4, and one of these patients also had
febrile neutropenia grade 3, anaemia grade 3 and stomatitis grade
3. The fourth patient had stomatitis grade 3 and treatment with
capecitabine was interrupted.
The significant toxicities observed after multiple administra-
tions of dose level 5 indicated that this recommended dose level
was safe during cycle 1, but was too toxic for repeated cycles.
Therefore, the dose of indisulam was further reduced to
500mgm
 2 (dose level 7, Table 2a) and an amended study was
initiated to investigate safety at repeated cycles. To investigate a
potential time-dependent pharmacokinetic interaction between
indisulam and capecitabine, the additional patients had full
pharmacokinetic sampling of indisulam and capecitabine during
cycle 1 and 2 and were assessed for DLT at both cycles. In this
amended study, nine eligible patients were treated with
500mgm
 2 indisulam in combination with 1250mgm
 2 BID
capecitabine. One patient had dose-limiting stomatitis grade 3 at
cycle 1 and another patient had dose-limiting hand/foot reaction
grade 3 during treatment cycle 2. Generally, this dose level was
adequately tolerated and was considered safe for multiple
treatment cycles.
Tables 3a and 3b show a summary of treatment-related adverse
events. Haematological and non-haematological toxicities were
observed more frequently at higher dose levels. The most frequent
grade 3–4 haematological toxicities related to study treatment
during cycle 1 were thrombocytopenia (four patients) and
neutropenia (three patients) (Table 3a). Two patients had febrile
Table 1 Patient characteristics at screening
N¼35
Gender
Male 22 (63%)
Female 13 (37%)
Age
Median 56
Range 20–70
Race
Caucasian 35 (100%)
Tumour type
Pancreas 10 (29%)
ACUP 5 (14%)
Colon 5 (14%)
Stomach 3 (9%)
Rectum 2 (6%)
NSCLC 2 (6%)
Oesophagus 1 (3%)
Ewing bone sarcoma 1 (3%)
Sclerosing osteosarcoma 1 (3%)
Melanoma 1 (3%)
Cholangiocarcinoma 1 (3%)
Squamous cell carcinoma 1 (3%)
Thymoma 1 (3%)
Endometrium 1 (3%)
KPS performance status
70 14 (40%)
80 10 (29%)
90 8 (23%)
100 3 (9%)
Time since diagnosis (months)
Median 11
Range 0–108
Metastatic/locally advanced disease
Metastatic 30 (86%)
Locally advanced 5 (14%)
Previous therapy
Chemotherapy 22 (63%)
Radiotherapy 12 (34%)
Surgery 23 (66%)
Other 4 (11%)
Table 2a Doses of indisulam and capecitabine and number of patients
included per dose level
Dose level
Indisulam
(mgm
 2) day 1
capecitabine (mgm
 2)
BID days 1–14 N
1 350 1000 3
2 350 1250 4
3 500 1250 6
4 600 1250 4
5 700 1250 7
6 800 1250 2
7 500 1250 9
Table 2b Number of cycles per patient
Number of cycles N
1–3 20 (57%)
4–6 7 (20%)
46 8 (23%)
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toxicities related to study treatment were stomatitis (12 patients),
diarrhoea (10 patients), hand-foot syndrome (nine patients) and
nausea (nine patients) (Table 3b). The occurrence of severe
adverse events (CTC grade 3 and 4) in cycle 1 and in cycle 2 is
depicted in Figure 1. This bar chart demonstrates that severe
adverse events were less frequently observed in cycle 1 than in
cycle 2.
The main grade 1–2 adverse events were anaemia, diarrhoea,
nausea and vomiting (Table 3b). ECG analysis showed that
indisulam did not have any cardiac effect.
A total of 16 patients (46%) went off-study due to progressive
disease according to RECIST criteria, seven (20%) due to clinical
progression, seven (20%) due to adverse events, three (8.6%)
because of no further clinical benefit (physicians decision), one
patient because the delay between treatment cycles was greater
than 2 weeks (protocol deviation), and one because of an abnormal
bilirubin level grade 3. Seven patients (20%) died on study, defined
as within 30 days of the last intake of study treatment.
Response
Thirty patients were evaluable for tumour response. Five patients
(14%) could not be evaluated because they did not receive at least
two cycles of treatment. Two patients had confirmed partial
response (6%), 17 patients (49%) had stable disease and 11
patients (31%) showed disease progression.
Population pharmacokinetics
Plasma samples for pharmacokinetic studies were obtained from
33 patients at cycle 1 for both indisulam and capecitabine. Two
patients were not evaluable for pharmacokinetic assessment. At
cycle 2, additional pharmacokinetic sampling was performed in
eight patients. For indisulam, in total 573 pharmacokinetic
samples were available from 41 treatment cycles (14 per cycle).
During cycle 1, the previously developed population pharmaco-
kinetic model adequately described the non-linear
pharmacokinetic profile of indisulam. Model-based predictions
corresponded well to the observed indisulam concentrations at
cycle 1 (data not shown). No difference was observed between
pharmacokinetic data from a phase I mono-therapy study and
cycle 1 of the current combination study. This indicates that
capecitabine does not interact with indisulam pharmacokinetics at
treatment cycle 1.
However, plasma concentrations of indisulam at cycle 2 were
much higher than expected. This is illustrated in Figure 2. Patient
A and B were treated during the initial part of the study. Patient A
was treated with 350mgm
 2 of indisulam (level 2) at cycle 1 and
Table 3a Treatment-related NCI-CTC grade 3–4 hematological lab
values during cycle 1
Dose level 1 2 3 and 7 4 5 6 Total
number of
patients treated n¼3 n¼4 n¼15 n¼4 n¼7 n¼2 n¼35
Thrombocytopenia 0 0 1 0 1 2 4 (11%)
Neutropenia 0 0 1 0 0 2 3 (9%)
Leukocytopenia 0 0 0 0 0 2 2 (6%)
Anaemia 0 0 0 0 1 0 1 (3%)
Table 3b Treatment-related non-haematological adverse events (observed in at least two patients) during cycle 1
Dose level 1 2 3 and 7 4 5 6 Total
number of patients treated n¼3 n¼4 n¼15 n¼4 n¼7 n¼2 n¼35
NCI-CTC grade 1–2 3–4 1–2 3–4 1–2 3–4 1–2 3–4 1–2 3–4 1–2 3–4 1–2 3–4
Stomatitis — — — — 5 1 1 — 3 — 2 — 11 (31%) 1 (3%)
Diarrhoea — — 2 — 3 1 1 — 3 — — — 9 (26%) 1 (3%)
Hand-foot syndrome — — — — 4 — 2 — 2 — 1 — 9 (26%) 0 (0%)
Nausea — — 1 — 3 — — — 4 — 1 — 9 (26%) 0 (0%)
Vomiting — — 1 — 2 — 1 — 2 — 1 — 7 (20%) 0 (0%)
Fatigue — — — — 3 — — — — 1 — — 3 (9%) 1 (3%)
Abdominal pain — — — — 1 — — — 1 1 1 — 3 (9%) 1 (3%)
Oedema — — 1 — — — — — 2 — — — 3 (9%) 0 (0%)
Alopecia — — — — — — — — 1 — 2 — 3 (9%) 0 (0%)
Anorexia — — — — 1 — — — 2 — — — 3 (9%) 0 (0%)
Constipation — — — — — 1 1 — — — 1 — 2 (6%) 1 (3%)
Epistaxis — — — — 2 — — — — — — — 2 (6%) 0 (0%)
Dyspepsia/pyrosis — — — — 2 — — — — — — — 2 (6%) 0 (0%)
Flatulence/meteorism — — — — — — — — 2 — — — 2 (6%) 0 (0%)
Hiccups — — — — 2 — — — — — — — 2 (6%) 0 (0%)
For events not included in NCI-CTC: mild¼grade 1; moderate¼grade 2; severe¼grade 3.
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Figure 1 Graphical representation of severe (grade 3 and 4) adverse
events in cycle 1 and in cycle 2.
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sthe corresponding AUC was 0.21gl
 1h
 1. Assuming that the
individual pharmacokinetic parameters would not be significantly
different at cycle 2, the AUC after administration of the second
indisulam infusion (level 3) was expected to be 0.32gl
 1h
 1
for this patient. However, the observed AUC was 1.51gl
 1h
 1.
For patient B, the AUC after initial treatment with 500mgm
 2
indisulam (level 3) was 0.42gl
 1h
 1 and the expected AUC
value for cycle 2 (level 4) was 0.53gl
 1h
 1. However, the observed
AUC of 1.51gl
 1h
 1 was again much higher than expected,
suggesting a time-dependent pharmacokinetic interaction between
indisulam and capecitabine. This was confirmed in the amended
study. Without exception, six additional patients (level 7) were
much higher exposed to indisulam during cycle 2 than during
cycle 1.
For capecitabine and its metabolites, 883 samples were available
from 33 patients. Pharmacokinetic results are summarised in
Table 4. Data from the current study were compared to literature
data (Mackean et al, 1998; Reigner et al, 1998, 1999; Cassidy et al,
1999; Twelves et al, 1999). The exposure to capecitabine and its
metabolites in the current study was not statistically significantly
different from published data.
Pharmacokinetic–pharmacodynamic analysis
Severe adverse events (CTC grade 3 and 4) occurred in 11 out of 41
treatment cycles, which were assessed for pharmacokinetics. The
AUC of indisulam was significantly higher in these 11 cycles
(median 2.2gl
 1h
 1, range 0.7–5.7gl
 1h
 1) than in the
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Figure 2 Observed indisulam plasma concentrations at cycle 1 (J) and cycle 2 (K) for eight individual patients. Patients A and B received an escalated
indisulam dose at cycle 2. The broken line (- - - -) represents the expected concentration time profile if capecitabine did not interact with indisulam
pharmacokinetics. Patients C, D, E, F, G and H were included in the amended study and received both in cycle 1 and in cycle 2 500mgm
 2 indisulam.
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 1h
 1, range 0.2–4.3gl
 1h
 1)
(Mann–Whitney U test, P¼0.008). This indicates that high
exposure to indisulam was associated with higher risk of severe
adverse events. The highest exposure to indisulam (5.7gl
 1h
 1)
was observed in a patient who had dose-limiting neutropenia with
sepsis, leukocytopenia grade 4 and thrombocytopenia grade 3.
Exposure to the capecitabine metabolite 50-DFUR was not higher
in treatment cycles with grade 3 and 4 toxicities (Mann–Whitney
U test, P¼0.48).
DISCUSSION
In this study, treatment with indisulam in combination with
capecitabine was investigated in patients with solid tumours. We
demonstrated that 500mgm
 2 indisulam and 1250mgm
 2 BID
capecitabine is safe and well tolerated during multiple cycles.
The recommended dose for indisulam single agent therapy was
700mgm
 2 (Raymond et al, 2002). In this study, the combined
dose of 700mgm
 2 indisulam and 1250mgm
 2 BID capecitabine
was well tolerated during cycle 1. However, at cycle 2 and
subsequent cycles significant toxicities were observed, which
indicated that this dose level was too toxic for repeated cycles.
Therefore, the dose of indisulam was further reduced to
500mgm
 2 to investigate safety at multiple cycles. Of nine eligible
patients, only one patient experienced a dose-limiting toxicity,
which confirmed that 500mgm
 2 indisulam and 1250mgm
 2 BID
capecitabine is safe for multiple treatment cycles.
Two patients had partial response and 17 patients had stable
disease. Whether the combination of indisulam and capecitabine
has a clinical additive effect remains to be investigated in phase II
and III studies.
One subject died due to cardiac arrhythmia. However, ECG
recordings in all other subjects did not show cardiac effects.
Furthermore, in the extensive clinical development of indisulam,
no signs of increased risk on cardiac toxicity was noticed.
Continuous cardiac monitoring is therefore not deemed necessary
in future clinical trials.
The main dose-limiting toxicity was myelosuppression. Grade
3–4 non-haematological toxicities most frequently observed were
hand/foot reaction and stomatitis. Hand/foot reaction is dependent
on cumulative exposure to capecitabine (He ´nin et al, 2006). The
incidence of this adverse event was therefore expected to be higher
at cycle 2 than at cycle 1. However, the increased incidence of other
grade 3–4 toxicities was suggestive for a time-dependent drug–
drug interaction between indisulam and capecitabine.
The exposure to indisulam was highly increased in cycle 2,
which is likely due to a pharmacokinetic interaction with
capecitabine. It has been postulated that 5-FU, the active
metabolite of capecitabine, may interfere with the synthesis of
the cytochrome P450 isozyme CYP2C9 (Brown, 1999). This
isozyme is mainly responsible for the metabolism of indisulam
(Eisai Ltd., data on file). Thus, through inhibition of CYP2C9
synthesis, indisulam metabolism may be impaired. This same
type of interaction has been described for phenytoin and warfarin
in combination with 5-FU (Copur et al, 2001; Gilbar and Brodribb,
2001). Phenytoin and warfarin are also metabolised by CYP2C9.
In combination with 5-FU the clearances of these agents were
decreased and plasma concentrations were increased. As
5-FU downregulates the synthesis of CYP2C9 (Brown, 1999;
Copur et al, 2001; Gilbar and Brodribb, 2001), it is not surprising
that this interaction becomes relevant only during the second or
subsequent treatment cycles of the combination capecitabine and
indisulam. The results suggest that CYP2C9 activity is decreased
even after a 7-day dosing interval of capecitabine. This finding is in
agreement with the results of Konishi et al (2003), who
demonstrated that the decrease in phenytoin p-hydroxylation
after single doses of 5-FU or 50-DFUR was not fully resolved
after 7 days.
Owing to a time-dependent pharmacokinetic interaction
between the drugs, patients were exposed to higher concentrations
of indisulam during cycle 2 than during cycle 1 (Zandvliet et al,
2007). Accordingly, the incidence of severe toxicities was higher in
repeated treatment cycles. A dose of indisulam of 500mgm
 2 and
capecitabine 1250mgm
 2 BID is considered safe in multiple
treatment cycles. Future in vitro and animal studies may further
elucidate the mechanisms of the time-dependent interaction
between indisulam and capecitabine.
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Table 4 Summary of pharmacokinetic analysis of capecitabine and its metabolites 50-DFCR, 50-DFUR and 5-FU
Capecitabine 50-DFCR 50-DFUR 5-FU
Number of patients evaluable for PK assessment 32 32 32 33
Number of curves evaluable for PK assessment
a 40 40 40 41
Number of curves fitted to a 1-compartment model 29 26 35 35
Number of curves fitted to a 2-compartment model 11 14 5 6
Absorption rate constant of capecitabine (h
 1) mean
b 5.27
CV
b (%) 248%
Formation rate constant of metabolite (h
 1) mean
b 2.60 3.71 3.96
CV
b (%) 139% 170% 154%
Absorption lag time of capecitabine (h) mean
b 0.57
CV
b (%) 109%
Formation lag time of metabolite (h) mean
b 0.53 0.74 0.73
CV
b (%) 101% 90% 111%
Terminal half-life (h) mean
b 0.73 0.30 1.03 0.83
CV
b (%) 646% 852% 47% 320%
AUC (mgl
 1h
 1) mean
b 7.71 12.5 9.36 1.29
Normalized AUC
c (mgl
 1h
 1) mean
b 6.67 10.8 8.09 0.98
CV
b (%) 91% 99% 40% 65%
aEight patients were assessed for capecitabine pharmacokinetics during two cycles.
bGeometric means and geometric coefficients of variance (interindividual variability) are
reported.
cAUC values were normalised to 2000mg doses of capecitabine.
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